SHANGHAI, April 23, 2023 /PRNewswire/ — Belief BioMed Group (BBM), an industry-leading biotech company focusing on innovative gene therapies, announced today the completion of patient dosing in its Phase III Registrational Clinical Trial (CTR20212816) of BBM-H901, a gene therapy for…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.